Molina Healthcare (NYSE:MOH) Announces Earnings Results, Misses Estimates By $3.18 EPS

Molina Healthcare (NYSE:MOH) announced its earnings results on Thursday. The company reported ($2.75) EPS for the quarter, missing the consensus estimate of $0.43 by ($3.18), FiscalAI reports. Molina Healthcare had a return on equity of 22.95% and a net margin of 1.98%.The business had revenue of $11.38 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the prior year, the business posted $5.05 earnings per share. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. Molina Healthcare updated its FY 2026 guidance to 5.000- EPS.

Molina Healthcare Trading Down 28.5%

MOH stock traded down $50.41 during midday trading on Friday, hitting $126.44. The stock had a trading volume of 5,390,506 shares, compared to its average volume of 1,554,154. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.92. The firm has a market cap of $6.85 billion, a P/E ratio of 7.84 and a beta of 0.49. The business has a fifty day moving average price of $173.55 and a two-hundred day moving average price of $171.21. Molina Healthcare has a 1-year low of $125.00 and a 1-year high of $359.97.

Wall Street Analysts Forecast Growth

MOH has been the topic of several analyst reports. Jefferies Financial Group set a $160.00 target price on Molina Healthcare in a report on Tuesday, December 16th. Weiss Ratings restated a “sell (d+)” rating on shares of Molina Healthcare in a research report on Thursday, January 22nd. Barclays lifted their price target on Molina Healthcare from $144.00 to $164.00 and gave the company an “underweight” rating in a research note on Monday, January 5th. Wall Street Zen downgraded Molina Healthcare from a “hold” rating to a “sell” rating in a research note on Saturday, October 25th. Finally, Truist Financial set a $175.00 target price on shares of Molina Healthcare in a research report on Friday, October 24th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $182.64.

Insider Activity at Molina Healthcare

In other news, Director Richard M. Schapiro sold 357 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $143.02, for a total transaction of $51,058.14. Following the completion of the sale, the director owned 11,352 shares of the company’s stock, valued at $1,623,563.04. This trade represents a 3.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 1.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Molina Healthcare

Institutional investors have recently modified their holdings of the company. MUFG Securities EMEA plc acquired a new stake in Molina Healthcare in the 2nd quarter valued at $48,000. Parallel Advisors LLC lifted its stake in shares of Molina Healthcare by 80.3% in the third quarter. Parallel Advisors LLC now owns 898 shares of the company’s stock valued at $172,000 after buying an additional 400 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Molina Healthcare by 30.4% during the second quarter. Smartleaf Asset Management LLC now owns 690 shares of the company’s stock valued at $205,000 after buying an additional 161 shares during the last quarter. Baird Financial Group Inc. bought a new stake in shares of Molina Healthcare during the first quarter worth about $210,000. Finally, State of Wyoming bought a new stake in shares of Molina Healthcare during the second quarter worth about $235,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Molina Healthcare News Summary

Here are the key news stories impacting Molina Healthcare this week:

• Positive Sentiment: Q4 revenue beat estimates — Molina reported $11.38B in quarterly revenue vs. ~$10.90B consensus and revenue was up ~8.3% year-over-year, showing top-line growth despite profitability issues. Molina Healthcare Reports Fourth Quarter and Year-End 2025 Financial Results
• Neutral Sentiment: Analysts and outlets are parsing the quarter and metrics (loss per share vs. year-ago EPS, membership, medical cost trends) to quantify the damage; these summaries provide context but don’t change the core story. Molina (MOH) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Neutral Sentiment: Media snapshots and roundups (SFGate, Benzinga) aggregate the quarter’s surprises and market reaction; useful for details but secondary to the guidance and analyst moves. Molina: Q4 Earnings Snapshot
• Negative Sentiment: Huge EPS miss: Molina reported a $2.75 loss per share vs. a $0.43 expected, a dramatic swing from $5.05 EPS a year earlier — the primary catalyst for the sell-off. Molina Healthcare Stock Falls 27%. Why Its Earnings Outlook Is So Bleak.
• Negative Sentiment: Guidance cut: FY2026 EPS guidance was set far below consensus (company guided to ~5.00 EPS vs. ~12.95 Street estimate), signaling sustained cost pressure from Obamacare/exchange plans. Molina Healthcare forecasts 2026 profit below estimates
• Negative Sentiment: Analyst reaction: Bank of America reiterated a Sell and set a $145 target, citing exchange contraction and policy uncertainty — adding downward pressure by signaling less upside. Molina Healthcare: Slashed Earnings Outlook, Exchange Contraction, and Policy Uncertainty Drive Underperform (Sell) Rating

Molina Healthcare Company Profile

Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.

The company traces its roots to the early 1980s, when Dr.